Sensorion announces that it has enrolled the first patient in its Phase 2a proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.

Platinum-based therapies, essential for the treatment of many cancers, cause permanent and irreversible ototoxicity or hearing loss in around 50-60% of adult patients and 90% of pediatric patients who survive cancer.

This indication represents a vast potential market, with over 500,000 patients concerned in the USA, the EU and Japan", stresses Sensorion, which expects to publish interim results from the study in the first half of 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.